Investor Information

News

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View News

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L EGFRm NSCLC

View News

More Information

Share Price

NASDAQ: SMMT

19.95 USD

11-Oct-2024 16:00 UTC-4

More Information

SEC Filings

Statement of changes in beneficial ownership of securities

View News

More Information

Email Alerts